Understanding and Communicating Risk: Assessing Both Relative and Absolute Risk Is Absolutely Necessary

*JID Innovations* (2022);2:100097 doi:10.1016/j.xjidi.2022.100097

**TO THE EDITOR**

Clinicians make medical decisions that require risk assessment on a daily basis. Ordering a test, prescribing a medication, and performing a procedure are examples of decisions that involve risk—benefit assessments. Making the best decisions requires the ability to quantify risk; unfortunately, both patients and clinicians have showed suboptimal performance in this ability (Koo et al., 2017). Furthermore, how risks are presented has a significant effect on how they are understood (Stone et al., 2017). This leads to the key principle that one cannot fully understand risk without reporting both the absolute risk and the relative risk. Absolute risk can be expressed as the risk difference, also known as absolute risk reduction, which represents the absolute difference in the incidence of an event between an exposed and an unexposed group. From the example mentioned earlier, in the first scenario, adverse events occur in 100 of every 100,000 people or 0.1% of people aged ≤75 years with COVID-19, whereas 265 of every 100,000 people or 0.265% of people aged >75 years experience adverse events. The risk difference here is 0.265–0.1% or 0.165%. In the second scenario mentioned earlier, the risk difference is 53.2–30% or 23.2%. This means that in the first scenario, there are 165 more deaths per 100,000 people in the >75 years age group, whereas in the second scenario a

---

**Table 1. Summary of Risk Measures**

| Measure                  | Definition                                                                 | Formula                                      |
|--------------------------|---------------------------------------------------------------------------|----------------------------------------------|
| Risk                     | Number of events divided by the total population at risk                   | Risk = \# events / total population at risk  |
| Odds                     | Number of events divided by the number of nonevents in a population       | Odds = \# events in population A / \# nonevents in population A |
| RD or ARR                | Difference between two comparable risks, which is attributed to an exposure or treatment | Risk difference = Risk in exposed − Risk in unexposed |
| NNT                      | Number of people who need to receive an intervention or treatment prevent an adverse outcome | NNT = 1 / AR                                |
| Risk ratio or RR         | Quotient of two risks comparing exposed and unexposed individuals         | RR = Risk in exposed / Risk in unexposed    |
| OR                       | Quotient of two odds comparing exposed and unexposed individuals          | OR = Odds in exposed / Odds in unexposed   |

Abbreviations: AR, absolute risk; ARR, absolute risk reduction; NNT, number needed to treat; RD, risk difference; RR, relative risk.
higher prevalence of an adverse outcome in the control group translates into 23,200 more deaths per 100,000 people (Table 4). A frequently presented measurement derived from the absolute risk reduction is the number needed to treat, which is the inverse of the absolute risk reduction. The number needed to treat is generally applied to therapeutic interventions and represents the theoretical number of people who would need to receive an intervention, on average, for one person to benefit. Therefore, if a new COVID-19 treatment was associated with an absolute risk reduction of 0.165% compared with placebo, the number needed to treat would be 1 of 0.00165 or 606. The converse of the number needed to treat is the number needed to harm, which represents the theoretical

### Table 2. Table (2 × 2) for Adverse Outcomes at a Prevalence of 0.1%

| Age       | Adverse Outcome | No Adverse Outcome | Total |
|-----------|-----------------|--------------------|-------|
| <75 years | 100             | 99,900             | 100,000 |
| ≥75 years | y               | 100,000 − x        | 100,000 |

Abbreviations: RR, relative risk.

1. Calculation of absolute number of adverse outcomes for population aged ≥75 years on the basis of OR

\[
OR = \frac{\text{Odds of an adverse outcome in people 75 years and older}}{\text{Odds of an adverse outcome in people under 75 years old}}
\]

\[
2.65 = \frac{\text{Odds of adverse outcome in people 75 years and older}}{\text{100}}
\]

\[
\text{Odds of adverse outcome in people 75 years and older} = 2.65 \times \frac{100}{99,900}
\]

\[
x = 0.00265265
\]

\[
y = 0.00264563 = 264.5 \text{ per 100,000}
\]

2. Calculation of RR

\[
RR = \frac{\text{Risk of an adverse outcome in people 75 years and older}}{\text{Risk of an adverse outcome in people under 75 years old}}
\]

\[
RR = \frac{2.65}{100} = 2.65
\]

### Table 3. Table (2 × 2) for Adverse Outcomes at a Prevalence of 30%

| Age       | Adverse Outcome | No Adverse Outcome | Total |
|-----------|-----------------|--------------------|-------|
| <75 years | 30,000          | 70,000             | 100,000 |
| ≥75 years | y               | 100,000 − y        | 100,000 |

Abbreviations: RR, relative risk.

1. Calculation of absolute number of adverse outcomes for population aged ≥75 years on the basis of OR

\[
OR = \frac{\text{Odds of an adverse outcome in people 75 years and older}}{\text{Odds of an adverse outcome in people under 75 years old}}
\]

\[
2.65 = \frac{\text{Odds of adverse outcome in people 75 years and older}}{\text{30,000}}
\]

\[
\text{Odds of adverse outcome in people 75 years and older} = 2.65 \times \frac{30,000}{70,000}
\]

\[
y = 0.53177 = 53.177 \text{ per 100,000}
\]

2. Calculation of RR

\[
RR = \frac{\text{Risk of an adverse outcome in people 75 years and older}}{\text{Risk of an adverse outcome in people under 75 years old}}
\]

\[
RR = \frac{1.77}{30,000} = 1.77
\]
Whereas at high outcome prevalence, the OR and RR are quite different. RR, relative risk.

Outcome. Note that at low outcome prevalence in the control population, the OR is fairly close to the RR, whereas at high outcome prevalence, the OR and RR are quite different. RR, relative risk.

Figure 1. Change in RR for a given OR with changing outcome prevalence. Change in RR for an adverse outcome given a fixed OR of 2.65 (experimental: control populations) as the prevalence of the adverse outcome increases. From an individual’s perspective, generally an absolute risk gives values that are easily interpreted into what risks they can expect when deciding between possible options (Noordzij et al., 2017), and presentation of the absolute risk has been shown to be more effective in communicating with patients (Zipkin et al., 2014). A recent study examining the risk of adverse outcomes after COVID-19 mRNA vaccines illustrates this point (Klein et al., 2021). The relative risk of thrombotic thrombocytopenic purpura in the first 21 days after mRNA vaccination was 2.60 (albeit statistically not different from the control interval), which at first glance would seem alarming. However, the number of events in the 21-day risk interval was 9.1 per million person-years, whereas the number of events in the comparison interval (22—42 days after the most recent dose) was 5.5 per million person-years. The absolute risk difference was 3.6 cases of thrombotic thrombocytopenic purpura per million person-years, slightly more than half the risk of death by lightning strike in the population of the South African Highveld (Blumenthal, 2005), which is a more reassuring figure.

Risk—benefit and cost—benefit analyses, which are frequently used for decision-making, rely on absolute risks rather than relative risks. An important recent example of a risk—benefit analysis involved was the emergence of thrombotic events associated with the administration of the Janssen COVID-19 vaccine (MacNeil et al., 2021). On 13 April 2021, the Centers for Disease Control and Prevention and the Food and Drug Administration recommended pausing of the administration of this vaccine after six cases of cerebral venous thrombosis with thrombocytopenia were reported. By 21 April 2021, approximately 7.98 million doses of the Janssen COVID-19 vaccine had been administered in the United States, and a total of 12 cases of cerebral venous thrombosis had been reported (See et al., 2021). If the at-risk period is assumed to be about 3 weeks after vaccination, this corresponds to an approximate incidence of 26 cases of cerebral venous thrombosis per million person-years. To put this in context, the background incidence of cerebral venous thrombosis has been estimated at between 2 and 5 cases per million population per year, although some studies have reported as high as 15.7 cases per million per year (Devasagayam et al., 2016). Thus, the relative risk of cerebral venous thrombosis among Janssen vaccine recipients (using the background population figure of five per million for comparison) was 26 of 5 or 5.2, which is alarming. Examination of only the relative risk here would likely have completely halted administration of this vaccine.

However, the Advisory Committee on Immunization Practices used the absolute risks and benefits and calculated the number of hospitalizations, intensive care unit admissions, and deaths prevented per million Janssen COVID-19 vaccine doses administered (Centers for Disease Control and Prevention, 2021). Comparing the risk of hospitalization, intensive care unit admission, and death due to COVID-19 for females aged 18—49 (the highest risk group for this thrombosis syndrome), for every expected case of vaccine-associated thrombosis, 297 hospitalizations, 56 intensive care unit admissions, and six deaths would be prevented by administering the vaccine. These comparisons were even more dramatic for women aged ≥50 years because there would be an expected 2,454 hospitalizations, 661 intensive care unit admissions, and 394 deaths prevented for every expected case of vaccine-associated thrombosis. The benefit of vaccination clearly outweighed the risk, and the use of the Janssen vaccine resumed in the United States.

Understanding common measurements of risk presented in medical literature is essential for placing the risks of diagnostic and therapeutic interventions into context and for communicating those risks with

Table 4. Risk Difference in Absolute and Relative Numbers

| Age Category | Absolute Risk | Risk Difference |
|--------------|---------------|----------------|
| Prevalence of an adverse outcome of 0.1% | | |
| Adverse outcome in people aged ≥75 years | 265 of every 100,000 | 165 per 100,000 |
| Adverse outcome in people aged <75 years | 100 of every 100,000 | or 0.165% |
| Prevalence of an adverse outcome of 30% | | |
| Adverse outcome in people aged ≥75 years | 53,200 of every 100,000 | 23,200 per 100,000 |
| | 100,000 | or 23.2% |
| Adverse outcome in people aged <75 years | 30,000 of every 100,000 | |
patients. Relative and absolute risk measures are complementary, and both should be presented when medical decisions are made.

Data availability statement
No datasets were generated or analyzed during this study.

ORCIDs
Sofia Zavala: http://orcid.org/0000-0003-1269-2959
Jason E. Stout: http://orcid.org/0000-0002-6698-8176

AUTHOR CONTRIBUTIONS
Conceptualization: SZ, JES; Supervision: JES; Writing - Original Draft Preparation: SZ; Writing - Review and Editing: SZ, JES

CONFLICT OF INTEREST
The authors state no conflict of interest.

Sofia Zavala1 and Jason E. Stout1,*
1Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
*Corresponding author
Correspondence: jason.stout@dm.duke.edu

REFERENCES
Blumenthal R. Lightning fatalities on the South African Highveld: a retrospective descriptive study for the period 1997 to 2000. Am J Forensic Med Pathol 2005;26:66–9.
Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021;16:e0247461.
Centers for Disease Control and Prevention (U.S.). Vaccines & Immunizations: individual-level risk-benefit analysis. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/risk-benefit-analysis.html; 2021. (accessed November 9, 2021).
Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke 2016;47:2180–2.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021;326:1390–9.
Koo K, Brackett CD, Eisenberg EH, Kieffer KA, Hyams ES. Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. PLoS One 2017;12:e0190357.
MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep 2021;70:651–6.
Noordzij M, van Diepen M, Caskey FC, Jager KJ. Relative risk versus absolute risk: one cannot be interpreted without the other. Nephrol Dial Transplant 2017;32(suppl 2):ii13–8.
See I, Su JR, Lale A, Woo BJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021;325:2448–56.
Stone ER, Brune de Bruin W, Wilkins AM, Boker EM, MacDonald Gibson J. Designing graphs to communicate risks: understanding how the choice of graphical format influences decision making. Risk Anal 2017;37:612–28.
Stone ER, Gabard AR, Groves AE, Lipkus IM. Effects of numerical versus foreground-only icon displays on understanding of risk magnitudes. J Health Commun 2015;20:1230–41.
Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med 2014;161:270–80.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/